AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30420092 — intervention group
Group type: COMPARATOR
Intervention: Constant supervision in surgical training
Number of subjects: 0
Study 30200394 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS⁺Lr&amp;Z (Oral Rehydration Solution enriched with Lactobacillus reuteri DSM 17938 and zinc)
Number of subjects: 51
Study 30200394 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (ORS-Lr&amp;Z)
Number of subjects: 51
Study 27232649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betrixaban (80 mg once daily for 35 to 42 days)
Number of subjects: 7513
Study 27232649 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Number of subjects: 7513
Study 25306266 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300 g/d)
Number of subjects: 72
Study 25306266 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt (300 g/d)
Number of subjects: 72
Study 22574586 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingchang Huashi Recipe (QHR) and Guanchang Recipe (GR) in the active stage, Fuzheng Qingchang Recipe in the remission stage
Number of subjects: 53
Study 22574586 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enteric coated tablet (MSRT, 1.0 g, 4 times daily) in the active stage, MSRT (0.5 g, three times daily) in the remission stage
Number of subjects: 53
Study 20099988 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 10 mg/kg
Number of subjects: 16
Study 20099988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17567399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford House recovery home
Number of subjects: 150
Study 17567399 — intervention group
Group type: COMPARATOR
Intervention: Usual after-care condition
Number of subjects: 150
Study 16623675 — intervention group
Group type: EXPERIMENTAL
Intervention: FX60S dialyzer
Number of subjects: 9
Study 16623675 — intervention group
Group type: COMPARATOR
Intervention: F60S dialyzer
Number of subjects: 9
Study 16623675 — intervention group
Group type: EXPERIMENTAL
Intervention: FX60S and F60S dialyzers
Number of subjects: 9
Study 12623762 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO) 500 mg daily for 2 days before omeprazole (OP) administration
Number of subjects: 18
Study 12623762 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (OP) alone
Number of subjects: 18
Study 12623762 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO)
Number of subjects: 18
Study 10556441 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator practice (Group A)
Number of subjects: 12
Study 10556441 — intervention group
Group type: COMPARATOR
Intervention: No practice (Group B)
Number of subjects: 12
Study 10556441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 8744579 — intervention group
Group type: EXPERIMENTAL
Intervention: Env 2‐3 in MTP‐PE/MF59
Number of subjects: 78
Study 8744579 — intervention group
Group type: COMPARATOR
Intervention: Env 2‐3 in MF59 without MTP‐PE
Number of subjects: 78
Study 1650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg
Number of subjects: 26
Study 1650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus lipiodol 10 ml
Number of subjects: 26
Study 1650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus MTXmc 150 mg
Number of subjects: 26
Study 1650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct puncture of the main trunk of the portal vein to infuse 500 mg of 5-FU during operation
Number of subjects: 26
Study 1650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of MMC 20 mg through a catheter inserted into the hepatic artery 4 weeks after operation
Number of subjects: 26
Study 6131800 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (40 mg in 5 ml i.m. three times daily for 6 days)
Number of subjects: 32
Study 6131800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml in normal saline i.m. three times daily for 6 days)
Number of subjects: 32
Study 31476429 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (GABAA agonist)
Number of subjects: 16
Study 31476429 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB agonist)
Number of subjects: 16
Study 31476429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (hypertonic saline with lidocaine)
Number of subjects: 48
Study 26013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment (hypertonic saline with lidocaine)
Number of subjects: 48
Study 26013322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden treatment (hypertonic saline with lidocaine)
Number of subjects: 48
Study 26013322 — intervention group
Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 48
Study 24755125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride modified release capsules (0.4 mg) alone and with mirabegron (100 mg once daily)
Number of subjects: 48
Study 24755125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron alone and with tamsulosin
Number of subjects: 48
Study 24755125 — intervention group
Group type: COMPARATOR
Intervention: Co-treatment of mirabegron and tamsulosin
Number of subjects: 48
Study 22735041 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH intervention (n=46)
Number of subjects: 96
Study 22735041 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 96
Study 19542666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 20
Study 19542666 — intervention group
Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiotherapy (3D CRT)
Number of subjects: 20
Study 18086052 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) gel
Number of subjects: 205
Study 18086052 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 205
Study 15331687 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 24
Study 12577350 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 57
Study 12577350 — intervention group
Group type: EXPERIMENTAL
Intervention: Xueshuantong (XST)
Number of subjects: 57
Study 10225504 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 12
Study 10225504 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy
Number of subjects: 12
Study 8547197 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by general practitioners (GP)
Number of subjects: 296
Study 8547197 — intervention group
Group type: COMPARATOR
Intervention: Usual practice follow-up in hospital clinics
Number of subjects: 296
Study 2147702 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group behavioral therapy including aerobic exercise (BE)
Number of subjects: 96
Study 2147702 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy only (B)
Number of subjects: 96
Study 2147702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise only (E)
Number of subjects: 96
Study 2147702 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 96
Study 2147702 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (BE, B, E)
Number of subjects: 96
Study 6986967 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT)
Number of subjects: 69
Study 6986967 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis (cranial irradiation and intrathecal methotrexate)
Number of subjects: 69
Study 6986967 — intervention group
Group type: COMPARATOR
Intervention: No CNS prophylaxis
Number of subjects: 69
Study 6986967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mercaptopurine and methotrexate for 18 months (for all children)
Number of subjects: 69
Study 6986967 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages I-II
Number of subjects: 69
Study 6986967 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages III-IV
Number of subjects: 69
Study 6986967 — intervention group
Group type: EXPERIMENTAL
Intervention: IF-RT in Stages III-IV
Number of subjects: 69
Study 31628035 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist luteal support (0.1 mg subcutaneously every other day, starting on day 3 after embryo transfer)
Number of subjects: 39
Study 31628035 — intervention group
Group type: COMPARATOR
Intervention: HCG luteal support (80 µg on day 3 after embryo transfer)
Number of subjects: 39
Study 28581821 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted case management (TACM)
Number of subjects: 113
Study 28581821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 113
Study 26181634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume aerobic exercise (300 min/wk)
Number of subjects: 400
Study 26181634 — intervention group
Group type: COMPARATOR
Intervention: Moderate-volume aerobic exercise (150 min/wk)
Number of subjects: 400
Study 24141239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg)
Number of subjects: 11
Study 24141239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21111377 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys™ with Hydraclear® Plus (senofilcon A) silicone hydrogel contact lenses, replaced every 2 weeks
Number of subjects: 0
Study 18540369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)
Number of subjects: 0
Study 18540369 — intervention group
Group type: COMPARATOR
Intervention: Non-combination therapy (IVIg alone)
Number of subjects: 0
Study 16509915 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible respiratory function monitor
Number of subjects: 35
Study 16509915 — intervention group
Group type: COMPARATOR
Intervention: Concealed respiratory function monitor
Number of subjects: 35
Study 14607447 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dobutamine infusion (10 microg/kg/min) in CHF patients
Number of subjects: 31
Study 14607447 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour dobutamine infusion (10 microg/kg/min) in CHF patients
Number of subjects: 31
Study 14607447 — intervention group
Group type: COMPARATOR
Intervention: Short-term dobutamine infusion (10 microg/kg/min) in matched controls
Number of subjects: 31
Study 14607447 — intervention group
Group type: COMPARATOR
Intervention: Short-term dobutamine infusion (10 microg/kg/min) in young controls
Number of subjects: 31
Study 10948076 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects (n=33)
Number of subjects: 198
Study 10948076 — intervention group
Group type: COMPARATOR
Intervention: Salt-resistant subjects (n=34)
Number of subjects: 198
Study 10948076 — intervention group
Group type: EXPERIMENTAL
Intervention: CA repeat polymorphism (14 repeats)
Number of subjects: 198
Study 10948076 — intervention group
Group type: COMPARATOR
Intervention: CA repeat polymorphism (23 repeats)
Number of subjects: 198
Study 9161192 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dental anaesthesia (EDA)
Number of subjects: 30
Study 9161192 — intervention group
Group type: COMPARATOR
Intervention: Placebo-EDA
Number of subjects: 30
Study 9161192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral injection
Number of subjects: 30
Study 1616866 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot LHRH analogue
Number of subjects: 0
Study 1616866 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study 1616866 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with LHRH analogue followed by deferred orchidectomy
Number of subjects: 0
Study 3908283 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg t.i.d.) plus dipyridamole (75 mg t.i.d.)
Number of subjects: 231
Study 3908283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two placeboes t.i.d.)
Number of subjects: 231
Study 31503147 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy
Number of subjects: 441
Study 31503147 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressing
Number of subjects: 441
Study 29357482 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before resistance exercise
Number of subjects: 8
Study 29357482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) for 24 h before resistance exercise
Number of subjects: 8
Study 27011114 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative QCA
Number of subjects: 30
Study 27011114 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative QCA
Number of subjects: 30
Study 27011114 — intervention group
Group type: COMPARATOR
Intervention: Control (without QCA)
Number of subjects: 30
Study 27011114 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative QCA (multicenter study)
Number of subjects: 30
Study 27011114 — intervention group
Group type: COMPARATOR
Intervention: Control (without QCA, multicenter study)
Number of subjects: 30
Study 25318029 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week MBSR intervention
Number of subjects: 58
Study 25318029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 22075649 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychological intervention (IPI)
Number of subjects: 128
Study 22075649 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling (Control)
Number of subjects: 128
Study 20418083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5992
Study 18631114 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention program in the intervention unit
Number of subjects: 0
Study 18631114 — intervention group
Group type: COMPARATOR
Intervention: Control unit without feedback intervention
Number of subjects: 0
Study 17994397 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF-based self-management of asthma
Number of subjects: 80
Study 17994397 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study 14722174 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 2% with epinephrine 1:200 000
Number of subjects: 58
Study 14722174 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with bupivacaine 0.5%
Number of subjects: 58
Study 11041320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone, 20 mg twice daily
Number of subjects: 30
Study 11041320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9048274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic timolol (50 microL of 0.5%)
Number of subjects: 8
Study 9048274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8312212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single insertion of vaginal tablets of prostaglandin E2 (PGE2) containing 3mg of dinoprostin
Number of subjects: 20
Study 8312212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single insertion of vaginal tablets of prostaglandin E2 (PGE2)
Number of subjects: 20
Study 8312212 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 singleton pregnant women)
Number of subjects: 20
Study 3518770 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 10 mg
Number of subjects: 10
Study 3518770 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 20 mg
Number of subjects: 10
Study 3518770 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide 250 micrograms
Number of subjects: 10
Study 3518770 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide 500 micrograms
Number of subjects: 10
Study 30853549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed N2O/O2 mixture
Number of subjects: 114
Study 30853549 — intervention group
Group type: COMPARATOR
Intervention: O2 (placebo)
Number of subjects: 114
Study 30577815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cd-stressed leaves and roots of ramie
Number of subjects: 0
Study 27022224 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus peginterferon alfa/ribavirin (pegIFN/RBV)
Number of subjects: 602
Study 27022224 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir plus peginterferon alfa/ribavirin (pegIFN/RBV)
Number of subjects: 602
Study 27022224 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus pegIFN/RBV
Number of subjects: 602
Study 24529502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy (75mg/day)
Number of subjects: 40
Study 24529502 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 22023551 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day
Number of subjects: 400
Study 22023551 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide 400 mg/day
Number of subjects: 400
Study 19682274 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% lidocaine pump spray (XPS)
Number of subjects: 124
Study 19682274 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo pump spray (PPS)
Number of subjects: 124
Study 17227903 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cytotoxic dose intensity through conventional means (support of hematopoietic growth factors, shortening treatment intervals)
Number of subjects: 0
Study 17227903 — intervention group
Group type: EXPERIMENTAL
Intervention: Megadose chemotherapy with the support of autologous bone marrow transplantation
Number of subjects: 0
Study 17227903 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care improvements (availability of hematopoietic growth factors and peripheral blood progenitor cells)
Number of subjects: 0
Study 15096921 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 65
Study 15096921 — intervention group
Group type: COMPARATOR
Intervention: Zyderm II collagen
Number of subjects: 65
Study 15096921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Botox + Zyderm II collagen)
Number of subjects: 65
Study 12235445 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (600 mg)
Number of subjects: 12
Study 12235445 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (300 mL)
Number of subjects: 12
Study 12235445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbyl palmitate (500 mg)
Number of subjects: 12
Study 12235445 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 9832592 — intervention group
Group type: EXPERIMENTAL
Intervention: SunSafe intervention promoting sun protection behavior through schools, day care centers, primary care practices, and recreation areas.
Number of subjects: 1930
Study 9832592 — intervention group
Group type: COMPARATOR
Intervention: Control towns (paired with intervention towns).
Number of subjects: 1930
Study 7989386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (40 mg of enoxaparin the evening before the operation and once a day subsequently)
Number of subjects: 185
Study 7989386 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 international units the evening before the operation and three times a day thereafter)
Number of subjects: 185
Study 2648897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15‐20 micrograms/kg
Number of subjects: 59
Study 2648897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution (meperidine 1.5 mg/kg, diazepam 0.2 mg/kg, atropine 0.02 mg/kg) 0.25 ml/kg
Number of subjects: 59
Study 2648897 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 59
Study 31856460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarsorrhaphy (Group A)
Number of subjects: 60
Study 31856460 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (Group B)
Number of subjects: 60
Study 31856460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 31685472 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS3123 200 mg
Number of subjects: 30
Study 31685472 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS3123 400 mg
Number of subjects: 30
Study 31685472 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS3123 600 mg
Number of subjects: 30
Study 31685472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31685472 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS3123 (all doses)
Number of subjects: 30
Study 31685472 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS3123 200 mg and 400 mg
Number of subjects: 30
Study 29286940 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus SLI P20D20 (20 cm H2O for 20 seconds)
Number of subjects: 100
Study 29286940 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus SLI P20D10 (20 cm H2O for 10 seconds)
Number of subjects: 100
Study 29286940 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus SLI P15D20 (15 cm H2O for 20 seconds)
Number of subjects: 100
Study 29286940 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus SLI P15D10 (15 cm H2O for 10 seconds)
Number of subjects: 100
Study 29286940 — intervention group
Group type: COMPARATOR
Intervention: CPAP (5 cm H2O)
Number of subjects: 100
Study 26345100 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM lithium disilicate veneering ceramic (CAD-on)
Number of subjects: 60
Study 26345100 — intervention group
Group type: COMPARATOR
Intervention: Layered zirconia veneering ceramic
Number of subjects: 60
Study 23500251 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel loading dose
Number of subjects: 50
Study 23500251 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg ticagrelor loading dose
Number of subjects: 50
Study 22338130 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic sevoflurane
Number of subjects: 80
Study 22338130 — intervention group
Group type: COMPARATOR
Intervention: Imported sevoflurane
Number of subjects: 80
Study 19018814 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied nightly for 6 weeks with occlusion
Number of subjects: 12
Study 19018814 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (not specified in detail)
Number of subjects: 12